CLINICAL TRIALS PROFILE FOR CYANOKIT
✉ Email this page to a colleague
All Clinical Trials for CYANOKIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03783091 ↗ | A Trial of Vitamin B12 in Septic Shock | Recruiting | Medical College of Wisconsin | Phase 2 | 2019-08-05 | This study will randomize 30 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to reduce vasopressor dose at 3 hours. |
NCT04054999 ↗ | Methylene Blue vs Cyanokit for Intraoperative Vasoplegic Syndrome in Liver Transplant Patients | Recruiting | Mayo Clinic | Phase 4 | 2021-12-30 | This study will evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery. |
NCT06160219 ↗ | Prophylactic Use of Hydroxycobolamin in Vasoplegic Syndrome in Adult Patients Undergoing Cardiopulmonary Bypass | Completed | Ain Shams University | Phase 2/Phase 3 | 2019-08-28 | Several studies have described the use of alternative drugs as methylene blue (MB) (3) other than the standard limited options of the use of vasopressors and systemic corticosteroids (4) especially in the face of increasing incidence of vasoplegic syndrome. Hydroxycobolamin (HCO) has been used for treating cyanide poisoning for more than 40 years. Persistant and significant hypertension occurred as a result of the ability of (HCO) to bind nitric oxide (NO) to form nitrocobalamin. In this prospective randomized controlled trial, we hypothesized that the prophylactic use of HCO in high risk patients after CPB may decrease the incidence of vasoplegia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CYANOKIT
Condition Name
Clinical Trial Locations for CYANOKIT
Trials by Country
Clinical Trial Progress for CYANOKIT
Clinical Trial Phase
Clinical Trial Sponsors for CYANOKIT
Sponsor Name